查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2011293

血糖值监测设备市场：2026-2032年全球市场预测（依设备类型、技术、应用、最终用户及通路划分）

Glucose Monitoring Devices Market by Device Type, Technology, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，血糖值监测设备市场价值将达到 93.4 亿美元，到 2026 年将成长至 103.6 亿美元，到 2032 年将达到 217.4 亿美元，复合年增长率为 12.81%。

主要市场统计数据
基准年 2025 93.4亿美元
预计年份：2026年 103.6亿美元
预测年份 2032 217.4亿美元
复合年增长率 (%) 12.81%

整体情况不断发展的血糖监测技术，包括技术进步、临床应用趋势和相关人员的优先事项。

血糖监测领域正经历快速的技术和商业性变革，彻底改变了临床医生、看护者和糖尿病患者管理血糖的方式。感测器小型化、数据连接和演算法分析的进步，以及不断发展的诊疗路径，正在为慢性病管理建立新的模式。本文概述了关键驱动因素和框架假设，为深入分析市场动态、市场区隔、区域差异和策略意义奠定了基础。

对技术、监管和商业性变革的整合进行详细分析，这些变革正在重新定义血糖监测的产品价值和护理路径。

血糖监测领域正经历一系列相互关联的变革，这些变革正在重新定义产品价值、医疗服务模式和竞争优势。感测器精度的提升，以及可长期佩戴和微创外形规格的出现，正将应用场景从传统的糖尿病管理扩展到预防性监测和手术全期护理。同时，可互通的数据生态系统和云端原生分析技术正在催生以远端监测、人群健康管理和决策支援为核心的新服务，从而改变了设备製造商和软体合作伙伴的预期。

对 2025 年关税变化将如何重塑整个血糖监测价值链的供应链、采购决策和商业策略进行策略评估。

2025年新关税措施的实施对整个血糖监测生态系统的供应链、筹资策略和定价产生了连锁反应。依赖国际采购零件的製造商面临着不断上涨的进口成本，迫使许多公司重新评估其采购地点并实现供应商多元化。对于在受影响地区以外拥有垂直整合製造地的公司而言，关税环境奖励其加快本地化进程并发展区域供应商，以确保生产的连续性并优化单位经济效益。

详细的細項分析揭示了设备类型、技术选择、临床应用、最终用户环境和分销管道如何决定差异化的创新和市场进入方式。

细分市场分析揭示了从设备类型、技术、应用、最终用户和分销管道等方面来看，创新轨迹和扩散模式存在差异。按设备类型分类，连续血糖监测 (CGM) 和瞬时血糖监测 (FGM) 与自我血糖监测 (SMBG) 形成鲜明对比。此外，CGM 本身又可细分为「个人」和「商用」两种，以满足不同的临床工作流程和支付方要求。技术差异进一步加剧了市场格局的细分。包括比色法和电化学安培法在内的侵入性方法与皮下感测器等微创方法以及利用光学光谱和经皮取的非侵入性方法并存，每种途径都面临着各自的监管挑战和用户体验方面的权衡取舍。

概述区域趋势，解释地理管理体制、支付方结构和医疗保健服务模式如何为血糖监测的实施创造不同的路径。

区域趋势对监管路径、报销模式和普及率产生了重大影响，在美洲、欧洲、中东、非洲和亚太地区带来了不同的战略挑战。在美洲，临床医生主导的推广应用和早期与支付方的合作推动了先进监测解决方案的快速普及，这些解决方案强调与电子健康记录和远端监测平台的互通性。这种环境有利于那些能够展示临床疗效、无缝整合到临床医生工作流程中并有效利用复杂报销框架的供应商。

对竞争格局进行评估，以确定决定血糖监测生态系统领导地位的策略性倡议、伙伴关係模式和能力差距。

血糖监测领域的竞争格局呈现出多元化的特点，既有成熟的医疗设备製造商，也有专注于糖尿病技术的公司，还有一些来自其他行业、提供软体和数据能力的参与企业。主要企业正大力投资于感测器效能、使用者体验和临床证据，以保持其差异化优势；而敏捷的新兴企业则专注于创新的外形规格、定价模式和软体驱动型服务。整个竞争格局中出现的策略性倡议包括：感测器和分析能力的垂直整合、拓展与保险公司和医疗保健系统的伙伴关係，以及透过有针对性的收购来加速互补技术的市场推广。

为製造商和相关人员提供切实可行的优先建议，以协调临床检验、商业化模式和业务永续营运，从而确保可持续的竞争优势。

产业领导者应优先考虑一系列切实可行的倡议，使产品开发、证据产生和商业性执行与不断变化的临床和支付方预期保持一致。首先，投资于能够将医疗设备效能转化为对病患和医疗保健系统有意义的结果的临床研究至关重要，这有助于推动医保报销谈判和产品差异化。为了补充临床证据，企业应开发模组化的商业模式，将医疗设备、资讯服务和教育支援结合，以提高客户留存率并实现收入来源多元化。

对用于评估医疗设备技术、临床应用和商业性趋势的调查设计、资料来源和分析方法进行透明的解释。

本研究整合了初级调查和二级调查的方法，并对目前血糖监测现状进行了严谨且可重复的评估。初级调查包括对临床医生、采购经理和技术主管的结构化访谈，并辅以技术检验和临床环境中的观察性评估，以支持关于可用性和整合挑战的论点。二级调查则利用同侪审查的临床文献、监管文件和公开资料，建构了关于技术性能和监管趋势的可靠证据基础。

策略整合强调整合技术、证据和商业策略如何决定哪些组织能够将创新转化为持久的临床和商业性影响。

总之，我们整合了本报告的关键主题，并重点阐述了其对相关人员在不断变化的血糖监测领域中的策略意义。技术创新正在催生更丰富、更连续的数据集，从而支持更积极主动的慢性病管理，但要充分发挥这一潜力，需要临床检验、监管策略和支付方合作的协调一致。成功整合卓越硬体、扩充性数据分析和以用户为中心的设计的市场参与企业，将在所有医疗保健机构中获得更广泛的应用。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章血糖值监测设备市场：依设备类型划分

  • 持续血糖监测
    • 个人
    • 专业的
  • 瞬时血糖监测
  • 自我血糖测量

第九章：血糖值监测设备市场：依技术划分

  • 侵袭型
    • 比色法
    • 电化学安培法
  • 微创
  • 非侵入性
    • 光学光谱学
    • 经皮取

第十章：血糖值监测设备市场：依应用领域划分

  • 妊娠糖尿病
  • 1型糖尿病
  • 2型糖尿病

第十一章血糖值监测设备市场：依最终用户划分

  • 门诊治疗
  • 居家照护
  • 医院
    • 私立医院
    • 公立医院

第十二章血糖值监测设备市场：依通路划分

  • 网路商店
    • 企业网站
    • EC平台
  • 离线

第十三章血糖值监测设备市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章血糖值监测设备市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章血糖值监测设备市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国血糖值监测设备市场

第十七章：中国血糖值监测设备市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AgaMatrix, Inc.
  • ARKRAY, Inc.
  • Ascensia Diabetes Care
  • Bigfoot Biomedical, Inc.
  • Dexcom, Inc.
  • EKF Diagnostics Holdings plc
  • ForaCare Inc.
  • GlucoRx Ltd
  • i-SENS, Inc.
  • Insulet Corporation
  • LifeScan, Inc.
  • Medtronic plc
  • Menarini Diagnostics
  • Nova Biomedical Corporation
  • Roche Diagnostics
  • Senseonics Holdings, Inc.
  • Sinocare Inc.
  • Tandem Diabetes Care, Inc.
  • Ypsomed AG
Product Code: MRR-436B79517C57

The Glucose Monitoring Devices Market was valued at USD 9.34 billion in 2025 and is projected to grow to USD 10.36 billion in 2026, with a CAGR of 12.81%, reaching USD 21.74 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.34 billion
Estimated Year [2026] USD 10.36 billion
Forecast Year [2032] USD 21.74 billion
CAGR (%) 12.81%

A comprehensive orientation to the evolving glucose monitoring landscape that frames technological advances, clinical adoption patterns, and stakeholder priorities

The landscape of glucose monitoring is undergoing rapid technological and commercial change, reshaping how clinicians, caregivers, and people with diabetes monitor glycemic control. Advances in sensor miniaturization, data connectivity, and algorithmic analytics are converging with shifting care pathways to create new models for chronic disease management. This introduction synthesizes core drivers and framing assumptions to set the stage for deeper analysis across market dynamics, segmentation, regional variation, and strategic implications.

In recent years, the focus has moved from episodic fingerstick testing toward continuous and real-time monitoring paradigms that emphasize longitudinal data and actionable insights. This transition has implications for device design, regulatory strategy, reimbursement engagement, and end-user experience. The result is a competitive environment where incumbent medical device manufacturers, specialized diabetes technology firms, and emerging digital health players are adjusting their propositions to emphasize connectivity, ease of use, and clinical integration. As stakeholders deliberate product development, clinical evidence generation, and commercialization pathways, a clear understanding of technological trends and regulatory pressures will be essential to navigate near-term disruptions and unlock sustained adoption.

An in-depth look at the converging technological, regulatory, and commercial shifts that are redefining product value and care pathways in glucose monitoring

The glucose monitoring sector is being transformed by a set of interrelated shifts that are redefining product value, care delivery, and competitive advantage. Sensor accuracy improvements combined with extended-wear and minimally invasive form factors are expanding use cases beyond conventional diabetes management into preventive monitoring and perioperative care. At the same time, interoperable data ecosystems and cloud-native analytics are enabling new services around remote monitoring, population health management, and decision support, which in turn alter expectations for device manufacturers and software partners.

Regulatory pathways are evolving to accommodate software as a medical device and adaptive algorithms, increasing emphasis on real-world evidence and post-market surveillance. Payer approaches are also changing, with value-based agreements and outcomes-based reimbursement models gaining traction in selective markets. These systemic shifts pressure firms to align clinical evidence strategies with commercial models and to invest in cross-disciplinary capabilities spanning hardware, software, and services. Consequently, leaders who integrate user-centered design, robust clinical validation, and scalable data infrastructures will capture outsized strategic options as the market matures.

A strategic appraisal of how tariff changes in 2025 reshaped supply chains, sourcing decisions, and commercial strategies across the glucose monitoring value chain

The imposition of new tariff measures in 2025 created a series of cascading effects on supply chains, sourcing strategies, and pricing decisions across the glucose monitoring ecosystem. Manufacturers relying on internationally sourced components faced increased landed costs, prompting many to re-evaluate sourcing footprints and supplier diversification. For companies with vertically integrated manufacturing outside affected jurisdictions, the tariff environment incentivized accelerated localization or regional supplier development to insulate production continuity and to manage unit economics.

Beyond direct cost pressures, tariffs influenced strategic choices around product configuration and procurement timing. Several firms prioritized higher-margin, subscription-based services and bundled offerings to protect revenue streams from one-time device price compression. Health systems and large purchasers reacted by updating procurement frameworks to incorporate total cost of ownership considerations rather than headline unit cost alone. Meanwhile, regulatory filings and supply chain certifications took on new importance as manufacturers sought to document origin and compliance, increasing programmatic costs for market entry. The cumulative effect has been a rebalancing of commercial playbooks toward resilience, supplier redundancy, and closer alignment between product roadmaps and procurement risk tolerance.

A granular segmentation synthesis revealing how device type, technology choices, clinical application, end-user settings, and distribution channels dictate differentiated innovation and go-to-market approaches

Segmentation analysis reveals differentiated innovation trajectories and adoption contours when examined across device type, technology, application, end user, and distribution channel. When framed by device type, Continuous Glucose Monitoring and Flash Glucose Monitoring contrast with Self Monitoring of Blood Glucose, while Continuous Glucose Monitoring itself bifurcates into Personal and Professional variants that address distinct clinical workflows and payer requirements. Technology distinctions further refine the landscape: Invasive approaches, including Colorimetric and Electrochemical Amperometric techniques, continue to coexist with Minimally Invasive options typified by subcutaneous sensors and Non Invasive modalities that leverage optical spectroscopy or transdermal extraction, each path presenting unique regulatory and user-experience trade-offs.

Application-based segmentation highlights that device design and service models are being tailored to the needs of gestational diabetes care, Type 1 diabetes management, and the larger population living with Type 2 diabetes, with clinical evidence and educational support varying accordingly. End-user segmentation splits demand across ambulatory care settings, home care environments, and hospital settings, where hospitals further divide into private and public institutions with different procurement constraints and clinical protocols. Finally, distribution channel distinctions shape commercialization strategies, with hospital pharmacies, online stores-encompassing company websites and e-commerce platforms-and retail pharmacies, made up of chain and independent outlets, enabling diverse go-to-market approaches. Taken together, these segmentation lenses demonstrate that product design, evidence generation, and commercial execution must be tightly aligned to the needs and constraints of targeted customer cohorts.

A regional intelligence overview explaining how geographic regulatory regimes, payer structures, and healthcare delivery models create distinct pathways for glucose monitoring adoption

Regional dynamics exert a material influence on regulatory pathways, reimbursement models, and adoption rates, producing distinct strategic imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, clinician-led adoption and early payer engagement have supported rapid uptake of advanced monitoring solutions, with an emphasis on interoperability with electronic health records and remote monitoring platforms. This environment has favored vendors who can demonstrate clinical outcomes and integrate seamlessly into clinician workflows while navigating complex reimbursement frameworks.

Europe, Middle East & Africa presents a heterogeneous landscape where regulatory standards, public procurement practices, and health system fragmentation require agile market-entry plans that account for national differences in approval timelines and payer expectations. Partnerships with local distributors and clinicians are often critical to build trust and to adapt evidence packages to local standards. The Asia-Pacific region features a broad spectrum of market maturity, with highly competitive urban centers advancing telehealth-enabled solutions and more price-sensitive markets emphasizing cost-effective devices and scalable distribution models. Across all regions, regulatory harmonization efforts and cross-border data governance debates will continue to shape commercialization strategies and product design priorities.

A competitive landscape assessment that identifies strategic moves, partnership patterns, and capability gaps that determine leadership in the glucose monitoring ecosystem

Competitive dynamics in glucose monitoring are characterized by a mix of established medical device manufacturers, specialized diabetes technology companies, and cross-sector entrants that bring software and data capabilities. Leading players have invested heavily in sensor performance, user experience, and clinical evidence to defend differentiated positions, while agile challengers focus on disruptive form factors, pricing models, and software-enabled services. Strategic initiatives observed across the competitive set include vertical integration of sensor and analytics capabilities, expansion of partnerships with payers and health systems, and targeted acquisitions to accelerate time to market for complementary technologies.

Companies that succeed are those that balance robust clinical validation with scalable manufacturing and a clear commercialization pathway that addresses the needs of providers, payers, and patients. Collaboration between hardware teams and algorithm developers has become a prerequisite for delivering meaningful insights rather than raw data. In addition, effective engagement with distribution partners and digital health platforms enhances reach and adherence, particularly in home care settings. As the industry evolves, the ability to orchestrate cross-functional capabilities and demonstrate real-world impact will determine which companies capture leadership positions.

Practical and prioritized recommendations for manufacturers and stakeholders to align clinical validation, commercialization models, and operational resilience for sustained advantage

Industry leaders should prioritize a set of pragmatic actions that align product development, evidence generation, and commercial execution to evolving clinical and payer expectations. First, investment in clinical studies that link device performance to meaningful patient and health system outcomes will be essential to support reimbursement dialogues and to differentiate offerings. Complementing clinical evidence, firms should develop modular commercial models that combine devices, data services, and educational support to increase stickiness and diversify revenue streams.

Operationally, companies must strengthen supply chain resilience through supplier diversification, manufacturing flexibility, and clear traceability of component origins. Strategic partnerships with digital health platforms and electronic health record providers will accelerate integration into clinical workflows and enhance perceived value among providers. Finally, organizations should build capability in post-market data analytics and regulatory compliance for adaptive software, enabling iterative improvement and sustained regulatory alignment. These combined actions will position firms to capture demand while managing cost and regulatory pressures across diverse markets.

A transparent explanation of research design, data sources, and analytical methods used to evaluate device technologies, clinical adoption, and commercial dynamics

This study synthesizes primary and secondary research approaches to provide a rigorous, reproducible assessment of the glucose monitoring landscape. Primary research included structured interviews with clinicians, procurement leaders, and technology executives, supplemented by technical validations and observational assessments in clinical environments to ground claims about usability and integration challenges. Secondary research drew on peer-reviewed clinical literature, regulatory documents, and public filings to construct a robust evidence base for technology performance and regulatory trends.

Analytical methods combined qualitative coding of interview data with thematic synthesis to identify recurring strategic priorities, while technology assessments evaluated sensor modalities against clinical criteria such as accuracy, wearability, and data interoperability. Care was taken to validate claims through triangulation across multiple sources and to flag areas where evidence remains emergent. Limitations of the approach are acknowledged, including variability in clinical practice across regions and the rapid pace of innovation that can shift competitive dynamics between research cycles. Where appropriate, recommendations reflect the degree of evidentiary confidence and highlight opportunities for targeted primary research to reduce uncertainty.

A strategic synthesis highlighting how integrated technology, evidence, and commercial strategies will determine which organizations convert innovation into durable clinical and commercial impact

The conclusion synthesizes the report's central themes and underscores the strategic implications for stakeholders seeking to navigate the evolving glucose monitoring environment. Technological innovation is enabling richer, continuous datasets that support more proactive chronic disease management, but realizing this promise requires alignment among clinical validation, regulatory strategy, and payer engagement. Market participants that successfully integrate hardware excellence with scalable data analytics and user-centered design will unlock broader adoption across care settings.

Operational resilience and adaptive commercialization models are equally important given geopolitical and trade disruptions that influence cost and supply continuity. Regional nuances will persist, demanding localized evidence and tailored engagement with clinicians and procurement entities. Ultimately, the competitive battleground will be defined by the ability to demonstrate measurable clinical and economic value while delivering an intuitive, low-friction experience for end users. Organizations that act decisively on these priorities will be best positioned to translate innovation into meaningful patient and system-level outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Glucose Monitoring Devices Market, by Device Type

  • 8.1. Continuous Glucose Monitoring
    • 8.1.1. Personal
    • 8.1.2. Professional
  • 8.2. Flash Glucose Monitoring
  • 8.3. Self Monitoring Of Blood Glucose

9. Glucose Monitoring Devices Market, by Technology

  • 9.1. Invasive
    • 9.1.1. Colorimetric
    • 9.1.2. Electrochemical Amperometric
  • 9.2. Minimally Invasive
  • 9.3. Non Invasive
    • 9.3.1. Optical Spectroscopy
    • 9.3.2. Transdermal Extraction

10. Glucose Monitoring Devices Market, by Application

  • 10.1. Gestational Diabetes
  • 10.2. Type 1 Diabetes
  • 10.3. Type 2 Diabetes

11. Glucose Monitoring Devices Market, by End User

  • 11.1. Ambulatory Care
  • 11.2. Home Care
  • 11.3. Hospitals
    • 11.3.1. Private Hospitals
    • 11.3.2. Public Hospitals

12. Glucose Monitoring Devices Market, by Distribution Channel

  • 12.1. Online Stores
    • 12.1.1. Company Websites
    • 12.1.2. E Commerce Platforms
  • 12.2. Offline

13. Glucose Monitoring Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Glucose Monitoring Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Glucose Monitoring Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Glucose Monitoring Devices Market

17. China Glucose Monitoring Devices Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. AgaMatrix, Inc.
  • 18.7. ARKRAY, Inc.
  • 18.8. Ascensia Diabetes Care
  • 18.9. Bigfoot Biomedical, Inc.
  • 18.10. Dexcom, Inc.
  • 18.11. EKF Diagnostics Holdings plc
  • 18.12. ForaCare Inc.
  • 18.13. GlucoRx Ltd
  • 18.14. i-SENS, Inc.
  • 18.15. Insulet Corporation
  • 18.16. LifeScan, Inc.
  • 18.17. Medtronic plc
  • 18.18. Menarini Diagnostics
  • 18.19. Nova Biomedical Corporation
  • 18.20. Roche Diagnostics
  • 18.21. Senseonics Holdings, Inc.
  • 18.22. Sinocare Inc.
  • 18.23. Tandem Diabetes Care, Inc.
  • 18.24. Ypsomed AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GLUCOSE MONITORING DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GLUCOSE MONITORING DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES GLUCOSE MONITORING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA GLUCOSE MONITORING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PERSONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PERSONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PERSONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PROFESSIONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PROFESSIONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PROFESSIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY SELF MONITORING OF BLOOD GLUCOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY SELF MONITORING OF BLOOD GLUCOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY SELF MONITORING OF BLOOD GLUCOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COLORIMETRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COLORIMETRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COLORIMETRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ELECTROCHEMICAL AMPEROMETRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ELECTROCHEMICAL AMPEROMETRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ELECTROCHEMICAL AMPEROMETRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY OPTICAL SPECTROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY OPTICAL SPECTROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY OPTICAL SPECTROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TRANSDERMAL EXTRACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TRANSDERMAL EXTRACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TRANSDERMAL EXTRACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY GESTATIONAL DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY GESTATIONAL DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY GESTATIONAL DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COMPANY WEBSITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COMPANY WEBSITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COMPANY WEBSITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2032 (USD MILLION)
  • TABLE 185. GCC GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GCC GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. GCC GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 188. GCC GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. GCC GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 190. GCC GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 191. GCC GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. GCC GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. GCC GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 194. GCC GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. GCC GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2032 (USD MILLION)
  • TABLE 218. G7 GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. G7 GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. G7 GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 221. G7 GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. G7 GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 223. G7 GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 224. G7 GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. G7 GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. G7 GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 227. G7 GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. G7 GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2032 (USD MILLION)
  • TABLE 229. NATO GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. NATO GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. NATO GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 232. NATO GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. NATO GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 234. NATO GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 235. NATO GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 236. NATO GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. NATO GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 238. NATO GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. NATO GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES GLUCOSE MONITORING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA GLUCOSE MONITORING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2032 (USD MILLION)